Wells Fargo lowered the firm’s price target on Oscar Health (OSCR) to $11 from $14 on lower odds for enhanced subsidy extension, while keeping an Underweight rating on the shares. The firm is updating estimates and model assumptions following Q3 and greater visibility into 2026 market dynamics. Wells sees Oscar Health as a clear share gainer in 2026, making it harder to underwrite MLR improvement.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OSCR:
- Cautious Outlook on Oscar Health: Sell Rating Amid Uncertain Profitability and Market Dynamics
- OSCR, ELV, CNC: Health Insurer Stocks on Watch as Trump Pushes ACA Funds Directly to Americans
- Oscar Health falls -14.3%
- Oscar Health price target raised to $13 from $11 at Barclays
- Oscar Health’s Earnings Call: Growth Amid Challenges